Compare Blackrock Inc (BLK) vs Bristol-Myers Squibb Co (BMY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackrock Inc vs Bristol-Myers Squibb Co — how do they compare? Blackrock Inc trades at $1,148.43 (market cap $177.92B), while Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B). The key difference: Blackrock Inc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BLK | BMY | |
|---|---|---|
Market Cap | $177.92B | $129.94B |
Volume | 641,547 | — |
Sector | Financials | Health |
52-Week High | $1.20K | $65.89 |
52-Week Low | $922.90 | $42.60 |
Enterprise Value | $179.02B | $163.92B |
Dividend Yield | 2% | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BLK trades at $1,131.40, down slightly by 0.44% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $24.22 billion for 2025, with net income of $5.55 billion, and has consistently beaten EPS estimates in recent quarters. Recent news highlights BlackRock's involvement in a major AI financing initiative with Nvidia and other firms.
The outlook remains positive given strong earnings performance and a consensus buy rating from analysts, with a price target of $1,350. Key risks include potential legal challenges from investor lawsuits and volatile cash flow trends, but institutional confidence and strategic partnerships provide a solid foundation for growth.
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →
